Combined evaluation of a panel of protein and miRNA serum-exosome biomarkers for pancreatic cancer diagnosis increases sensitivity and specificity

International Journal of Cancer

Volumn 136, Issue 11, 2015, Pages 2616-2627

  Madhavan, Bindhu ^a   Yue, Shijing ^a   Galli, Uwe ^a   Rana, Sanyukta ^a   Gross, Wolfgang ^a   Müller, Miryam ^a   Giese, Nathalia A ^a   Kalthoff, Holger ^b   Becker, Thomas ^b   Büchler, Markus W ^a   Zöller, Margot ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF KIEL   (Germany)

Author keywords

diagnosis; human biomarkers; oncomiR; pancreatic cancer initiating cell markers; serum exosomes

Indexed keywords

CD104 ANTIGEN; CD44V6 ANTIGEN; EPITHELIAL CELL ADHESION MOLECULE; LYMPHOCYTE ANTIGEN; MICRORNA; MICRORNA 1246; MICRORNA 3976; MICRORNA 4306; MICRORNA 4644; PEPTIDES AND PROTEINS; PROTEIN TSPAN8; SCATTER FACTOR RECEPTOR; TUMOR MARKER; UNCLASSIFIED DRUG;

ARTICLE; CANCER DIAGNOSIS; CANCER STAGING; CONTROLLED STUDY; EXOSOME; FLOW CYTOMETRY; HUMAN; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; PANCREAS CANCER; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; SERUM; BLOOD; DNA MICROARRAY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOLECULAR DIAGNOSIS; PANCREAS TUMOR; PROCEDURES;

EXOSOMES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; MOLECULAR DIAGNOSTIC TECHNIQUES; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PANCREATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84924874243     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29324     Document Type: Article

References (51)

1. Costello E, Greenhalf W, Neoptolemos JP,. New biomarkers and targets in pancreatic cancer and their application to treatment. Nat Rev Gastroenterol Hepatol 2012; 9: 435-44.
2. Fong ZV, Winter JM,. Biomarkers in pancreatic cancer: diagnostic, prognostic, and predictive. Cancer J 2012; 18: 530-8.
3. György B, Szabõ TG, Pásztõi M, et al. Membrane vesicles, current state-of-the-art: emerging role of extracellular vesicles. Cell Mol Life Sci 2011; 68: 2667-88.
4. Liu R, Chen X, Du Y, et al. Serum microRNA expression profile as a biomarker in the diagnosis and prognosis of pancreatic cancer. Clin Chem 2012; 58: 610-18.
5. Mathivanan S, Ji H, Simpson RJ,. Exosomes: extracellular organelles important in intercellular communication. J Proteomics 2010; 73: 1907-20.
6. Zöller M,. Tetraspanins: push and pull in suppressing and promoting metastasis. Nat Rev Cancer 2009; 9: 40-55.
7. Vlassov AV, Magdaleno S, Setterquist R, et al. Exosomes: current knowledge of their composition, biological functions, and diagnostic and therapeutic potentials. Biochim Biophys Acta 2012; 1820: 940-8.
8. Valadi H, Ekström K, Bossios A, et al. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 2007; 9: 654-9.
9. Gibbings DJ, Ciaudo C, Erhardt M, et al. Multivesicular bodies associate with components of miRNA effector complexes and modulate miRNA activity. Nat Cell Biol 2009; 11: 1143-9.
10. Lee Y, El Andaloussi S, Wood MJ,. Exosomes and microvesicles: extracellular vesicles for genetic information transfer and gene therapy. Hum Mol Genet 2012; 21: R125-34.
11. Hu G, Drescher KM, Chen XM,. Exosomal miRNAs: biological properties and therapeutic potential. Front Genet 2012; 3: 56.
12. Lee TH, D'Asti E, Magnus N, et al. Microvesicles as mediators of intercellular communication in cancer-the emerging science of cellular 'debris'. Semin Immunopathol 2011; 33: 455-67.
13. Arroyo JD, Chevillet JR, Kroh EM, et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci USA 2011; 108: 5003-8.
14. Bauer AS, Keller A, Costello E, et al. Diagnosis of pancreatic ductal adenocarcinoma and chronic pancreatitis by measurement of microRNA abundance in blood and tissue. PLoS One 2012; 7: e34151.
15. Lonardo E, Hermann PC, Heeschen C,. Pancreatic cancer stem cells-update and future perspectives. Mol Oncol 2010; 4: 431-42.
16. Abel EV, Simeone DM,. Biology and clinical applications of pancreatic cancer stem cells. Gastroenterology 2013; 144: 1241-8.
17. Wang H, Rana S, Giese N, et al. Tspan8, CD44v6 and alpha6beta4 are biomarkers of migrating pancreatic cancer-initiating cells. Int J Cancer 2013; 133: 416-26.
18. Ramachandran S, Palanisamy V,. Horizontal transfer of RNAs: exosomes as mediators of intercellular communication. Wiley Interdiscip Rev RNA 2012; 3: 286-93.
19. Rana S, Malinowska K, Zöller M,. Exosomal tumor microRNA modulates premetastatic organ cells. Neoplasia 2013; 15: 281-95.
20. Bhat K, Wang F, Ma Q, et al. Advances in biomarker research for pancreatic cancer. Curr Pharm Des 2012; 18: 2439-51.
21. Kogure T, Lin WL, Yan KI, et al. Intercellular nanovesicle-mediated microRNA transfer: a mechanism of environmental modulation of hepatocellular cancer cell growth. Hepatology 2011; 54: 1237-48.
22. Ishii K, Tahara T,. Resolving inhomogeneity using lifetime-weighted fluorescence correlation spectroscopy. J Phys Chem B 2010; 114: 12383-91.
23. Wang HX, Li Q, Sharma C, et al. Tetraspanin protein contributions to cancer. Biochem Soc Trans 2011; 39: 547-52.
24. Yue S, Mu W, Zöller M,. Tspan8 and CD151 promote metastasis by distinct mechanisms. Eur J Cancer 2013; 49: 2934-48.
25. Weiland M, Gao XH, Zhou L, et al. Small RNAs have a large impact: circulating microRNAs as biomarkers for human diseases. RNA Biol 2012; 9: 850-9.
26. Zen K, Zhang CY,. Circulating microRNAs: a novel class of biomarkers to diagnose and monitor human cancers. Med Res Rev 2012; 32: 326-48.
27. Gesierich S, Paret C, Hildebrand D, et al. Colocalization of the tetraspanins, CO-029 and CD151, with integrins in human pancreatic adenocarcinoma: impact on cell motility. Clin Cancer Res 2005; 11: 2840-52.
28. Kuhn S, Koch M, Nübel T, et al. A complex of EpCAM, claudin-7, CD44 variant isoforms, and tetraspanins promotes colorectal cancer progression. Mol Cancer Res 2007; 5: 553-67.
29. Rana S, Yue S, Stadel D, et al. Toward tailored exosomes: the exosomal tetraspanin web contributes to target cell selection. Int J Biochem Cell Biol 2012; 44: 1574-84.
30. Orian-Rousseau V, Morrison H, Matzke A, et al. Hepatocyte growth factor-induced Ras activation requires ERM proteins linked to both CD44v6 and F-actin. Mol Biol Cell 2007; 18: 76-83.
31. Jung T, Gross W, Zöller M,. CD44v6 coordinates tumor matrix-triggered motility and apoptosis resistance. J Biol Chem 2011; 286: 15862-74.
32. Wan C, Shen Y, Yang T, et al. Diagnostic value of microRNA for pancreatic cancer: a meta-analysis. Arch Med Sci 2012; 8: 749-55.
33. Kawaguchi T, Komatsu S, Ichikawa D, et al. Clinical impact of circulating miR-221 in plasma of patients with pancreatic cancer. Br J Cancer 2013; 108: 361-9.
34. Li A, Yu J, Kim H, et al. MicroRNA array analysis finds elevated serum miR-1290 accurately distinguishes patients with low-stage pancreatic cancer from healthy and disease controls. Clin Cancer Res 2013; 19: 3600-10.
35. Liu J, Gao J, Du Y, et al. Combination of plasma microRNAs with serum CA19-9 for early detection of pancreatic cancer. Int J Cancer 2012; 131: 683-91.
36. Brand RE, Nolen BM, Zeh HJ, et al. Serum biomarker panels for the detection of pancreatic cancer. Clin Cancer Res 2011; 17: 805-16.
37. Li A, Omura N, Hong SM, et al. Pancreatic cancers epigenetically silence SIP1 and hypomethylate and overexpress miR-200a/200b in association with elevated circulating miR-200a and miR-200b levels. Cancer Res 2010; 70: 5226-37.
38. Zhao C, Zhang J, Zhang S, et al. Diagnostic and biological significance of microRNA-192 in pancreatic ductal adenocarcinoma. Oncol Rep 2013; 30: 276-84.
39. Kong X, Du Y, Wang G, et al. Detection of differentially expressed microRNAs in serum of pancreatic ductal adenocarcinoma patients: miR-196a could be a potential marker for poor prognosis. Dig Dis Sci 2011; 56: 602-9.
40. Du Y, Liu M, Gao J, et al. Aberrant microRNAs expression patterns in pancreatic cancer and their clinical translation. Cancer Biother Radiopharm 2013; 28: 361-9.
41. Jaiswal R, Luk F, Gong J, et al. Microparticle conferred microRNA profiles-implications in the transfer and dominance of cancer traits. Mol Cancer 2012; 11: 37.
42. Pigati L,. Selective release of microRNA species from normal and malignant mammary epithelial cells. PLoS One 2010; 5: e13515.
43. Ali S, Saleh H, Sethi S, et al. MicroRNA profiling of diagnostic needle aspirates from patients with pancreatic cancer. Br J Cancer 2012; 107: 1354-60.
44. Takeshita N, Hoshino I, Mori M, et al. Serum microRNA expression profile: miR-1246 as a novel diagnostic and prognostic biomarker for oesophageal squamous cell carcinoma. Br J Cancer 2013; 108: 644-52.
45. Fu HL, Wu de P, Wang XF, et al. Altered miRNA expression is associated with differentiation, invasion, and metastasis of esophageal squamous cell carcinoma (ESCC) in patients from Huaian, China. Cell Biochem Biophys 2013; 67: 657-68.
46. Chen J, Yao D, Li Y, et al. Serum microRNA expression levels can predict lymph node metastasis in patients with early-stage cervical squamous cell carcinoma. Int J Mol Med 2013; 32: 557-67.
47. Jones CI, Zabolotskaya MV, King AJ, et al. Identification of circulating microRNAs as diagnostic biomarkers for use in multiple myeloma. Br J Cancer 2012; 107: 1987-96.
48. Persson H, Kvist A, Rego N, et al. Identification of new microRNAs in paired normal and tumor breast tissue suggests a dual role for the ERBB2/Her2 gene. Cancer Res 2011; 71: 78-86.
49. Ramsingh G, Koboldt DC, Trissal M, et al. Complete characterization of the microRNAome in a patient with acute myeloid leukemia. Blood 2010; 116: 5316-26.
50. Goff LA, Davila J, Swerdel MR, et al. Ago2 immunoprecipitation identifies predicted microRNAs in human embryonic stem cells and neural precursors. PLoS One 2009; 4: e7192.
51. Mo MH, Chen L, Fu Y, et al. Cell-free Circulating miRNA Biomarkers in Cancer. J Cancer 2012; 3: 432-48.